These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18625340)

  • 1. Src and focal adhesion kinase as therapeutic targets in cancer.
    Brunton VG; Frame MC
    Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
    Schwock J; Dhani N; Hedley DW
    Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase: a potential target in cancer therapy.
    van Nimwegen MJ; van de Water B
    Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal adhesion kinase as a cancer therapy target.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
    Schultze A; Fiedler W
    Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention.
    Parsons JT; Slack-Davis J; Tilghman R; Roberts WG
    Clin Cancer Res; 2008 Feb; 14(3):627-32. PubMed ID: 18245520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
    Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
    Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAK inhibitors in Cancer, a patent review.
    Lv PC; Jiang AQ; Zhang WM; Zhu HL
    Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta1 effects on endothelial monolayer permeability involve focal adhesion kinase/Src.
    Lee YH; Kayyali US; Sousa AM; Rajan T; Lechleider RJ; Day RM
    Am J Respir Cell Mol Biol; 2007 Oct; 37(4):485-93. PubMed ID: 17585111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of FAK in tumor metabolism and therapy.
    Zhang J; Hochwald SN
    Pharmacol Ther; 2014 May; 142(2):154-63. PubMed ID: 24333503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAK signaling in human cancer as a target for therapeutics.
    Lee BY; Timpson P; Horvath LG; Daly RJ
    Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H; Hu Z; Huiwen M; Zhijun L; Jiaojie Z; Xiaoyi Y; Xiujun C
    Biochem Biophys Res Commun; 2015 Aug; 464(2):422-7. PubMed ID: 26102035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting focal adhesion kinase in cancer-part I.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):713. PubMed ID: 21348852
    [No Abstract]   [Full Text] [Related]  

  • 18. Focal adhesion kinase as potential target for cancer therapy (Review).
    Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Wang ZG; Takaoka M
    Oncol Rep; 2009 Nov; 22(5):973-9. PubMed ID: 19787209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
    Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
    Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
    Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.